Drugs / SAPOSIN C (NON-GLYCOSYLATED)
SAPOSIN C (NON-GLYCOSYLATED)
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05291286 | Oct 2022 → Dec 2024 | chemotherapy-induced neuropathy | Bexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT04771897 | May 2021 → Oct 2024 | diffuse midline glioma, H3 K27M-mutant | Bexion Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04404569 | Jun 2020 → Sep 2024 | neoplasm | Bexion Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03967093 | Apr 2019 → Jan 2020 | neoplasm | Bexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02859857 | Sep 2016 → Jun 2019 | neoplasm | Bexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05322590 | Jan 2023 → Apr 2026 overdue | colorectal adenocarcinoma, sensory peripheral neuropathy | Bexion Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAPOSIN C (NON-GLYCOSYLATED) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594362 ↗ |
| Known as | BXQ-350 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04771897 ↗ |
| Known as | Saposin c recombinant | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594362 ↗ |
| Modality | Other / unclassified | “When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).” NCT02859857 ↗ |
| Route | Intravenous | “Administered as a Single Agent by Intravenous Infusion” NCT02859857 ↗ |